2-Oxoadipate dehydrogenase (E1a, also known as DHTKD1, dehydrogenase E1 and transketolase
domain-containing protein 1) is a thiamin diphosphate-dependent enzyme and part of
the 2-oxoadipate dehydrogenase complex (OADHc) in L-lysine catabolism. Genetic findings
have linked mutations in the DHTKD1 gene to several metabolic disorders. These include
alpha-aminoadipic and alpha-ketoadipic aciduria (AMOXAD), a rare disorder of L-lysine,
L-hydroxylysine, and L-tryptophan catabolism, characterized by clinical presentations
such as developmental delay, mild-to-severe intellectual disability, ataxia, epilepsy,
and behavioral disorders that cannot be currently managed by available treatments.
A heterozygous missense mutation, c.2185G>A (p. G729R), in DHTKD1 has been identified
in most AMOXAD cases. Here, we report that the G729R E1a variant when assembled into
OADHc in vitro displays a 50-fold decrease in catalytic efficiency for NADH production
and significantly reduced rate of glutaryl-CoA production by dihydrolipoamide succinyl-transferase
(E2o). However, the G729R E1a substitution did not affect any of the three side-reactions
associated solely with G729R E1a, prompting us to determine the structure-function
effects of this mutation. A multipronged systematic analysis of the reaction rates
in the OADHc pathway, supplemented with results from chemical cross-linking and hydrogen-deuterium
exchange MS, revealed that the c.2185G>A DHTKD1 mutation affects E1a-E2o assembly,
leading to impaired channeling of OADHc intermediates. Cross-linking between the C-terminal
region of both E1a and G729R E1a with the E2o lipoyl and core domains suggested that
correct positioning of the C-terminal E1a region is essential for the intermediate
channeling. These findings may inform the development of interventions to counter
the effects of pathogenic DHTKD1 mutations.
